ABSTRACT
Background and Objectives: - Carcinoma Breast is most common malignancy in females in USA and second among cases deaths in females (after lung cancer). There is considerable geographic , ethnic and racial variability in Breast cancer in evidence with about 5 fold variation throughout the world. Triple negative breast cancer is a heterogonous disease diagnosed by Immune Histo Chemistry (IHC).Triple Negative Breast cancer is characterized by tumor that do not express ER or PR and HER2neu . Proto typical Triple Negative Brest cancer is aggressive in nature and associate with poor prognosis. The Objectives of this study is to analyse the clinical and Pathological features of Triple Negative Breast Cancer and compare the result with similar studies in literature. Fifty Methods:- cases Triple negative Breast Cancer were included in this study. Clinical and pathological features and treatment were noted. Incidence Result:- of Triple Negative Breast Cancer was 35%. The median age of presentation was 45yrs. There were 4% males Triple negative Breast cancer cases out of female patients, most of patients were Pre (or) Perimenopausal(65%). 4% patients had family history of malignantly. Most common stage of presentation was stage III (46%). In Stage IV, Lung and bone metastasis was common. Ten Patients received Neoadjuvant chemo therapy (NACJ) and disease progressed in 4% while on Neoadjuvant chemotherapy, Even though 45 patients had surgery only 34 were eligible to received Adjuvant Radiotherapy. Total of 18% Patients had either progressive disease while on treatment (8%) (or) recurrence 10%. Eighteen percent patients died due to the disease. 33% patients on follow up. There were more Invasive Duct Cell carcinoma (IDCC) cases with medullary differentiations (or) Purse medullary Carcinomas (12%). No deaths Occur in the medullary variants TNBC. Majority of the tumor were high grade margins were negative in most of the cases. Incidence of Tri Inclusion:- ple negative breast cases was higher than western literature but comparable to Indian Studies. The age of Presentation was about 10 years younger than western data. Triple Negative Breast cancer was more common in young, pre (or) perimenopausal women. Small number of patients had family history, majority were state II (or) III. There was high number of progressive disease, recurrence and death while on the study (or) within less than 1 yr of treatment. Triple Negative Breast cancer is very aggressive disease with relatively better prognosis in the medullary variant Triple Negative Breast Cancer.
ABSTRACT
Neoadjuvant therapy refers to the systemic treatment of breast cancer prior to definitive surgical from size reduction before conservation therapy. Response to neoadjuvant chemotherapy is evaluated by the change in tumor size from pretreatment clinical and or radiologic measurement to post-treatment status. The spectrum of response to neoadjuvant chemotherapy varies from complete response, partial response, to non-response. This concept is the same in breast tumors as well as axillary lymph nodes. The presented case is a known case of Triple Negative Invasive Ductal carcinoma with Axillary involvement Right Breast since November 2020 and had undergone NeoadjuvantChemotherapy till February 2021,followed by surgical intervention in October 2022.
ABSTRACT
Resumen La dermatomiositis (DM) es un tipo de miopatía inflamatoria bien definida, inmunomediada, con afectación específica del músculo esquelético y con compromiso variable de piel y otros órganos. Se caracteriza por debilidad muscular proximal, lesiones cutáneas patognomónicas de dermatomiositis como el signo de Gottron, eritema violáceo o heliotropo, y evidencia de inflamación muscular por enzimas elevadas, cambios miopáticos en electromiografía y biopsia muscular anormal. Tiene una asociación bien establecida con diferentes tipos de cáncer pero es rara su asociación con cáncer de mama. Cuando se presentan de manera concomitante, su diagnóstico requiere un estudio multidisciplinario para orientar el origen paraneoplásico frente a una etiología propiamente autoinmune que requiera terapia inmunosupresora dirigida. Describimos el caso de una paciente con diagnóstico simultáneo de carcinoma infiltrante de mama triple negativo y criterios de dermatomiositis como manifestación paraneoplásica.
Abstract Dermatomyositis (DM) is a well-defined immune-mediated inflammatory myopathy, with specific involvement of skeletal muscle and variable involvement of skin and other organs. It is characterized by proximal muscle weakness, pathognomonic skin lesions of dermatomyositis such as Gottron's sign, violaceous or heliotrope rash, and evidence of muscle inflammation due to elevated enzymes, myopathic changes on electromyography, and abnormal muscle biopsy. It has a well-established association with different types of cancer, but its association with breast cancer is rare. When they occur concomitantly, their diagnosis requires a multidisciplinary study to confirm the paraneoplastic origin versus a primarily autoimmune etiology that may require targeted immunosuppressive therapy. We describe the case of a patient with a simultaneous diagnosis of triple-negative infiltrating breast carcinoma and criteria for dermatomyositis as a paraneoplastic manifestation.
Subject(s)
Female , Dermatomyositis , Triple Negative Breast Neoplasms , Raynaud Disease , Breast Neoplasms , MyositisABSTRACT
Purpose To explore the expression and clinical significance of CD47 in triple negative breast carcinoma (TNBC),and to analyze the relationship between CD47 expression and clinicopathologic features.Methods Immunohistochemical of Bond Polymer Refine Detection staining was performed on tissue array.It contains 185 cases of TNBC and 35 cases of non triple negative breast carcinoma (NTNBC).Then we observed the expression of CD47 in TNBC,and analyzed the relationship between the expression of CD47 and various clinical pathological characteristics.Results The expression of CD47 in tumor cells of TNBC was higher than that in NTNBC,and the difference was statistically significant (P ＜ 0.05).The CD47 expression rate in TNBC tumors was 52.3％.It was closely related to clinical stage (P ＜ 0.05),lymph node metastasis and distant metastasis (P ＜ 0.05) and vascular invasion (P ＜ 0.05).Conclusion The expression of CD47 is correlated with the clinical stage,lymph node metastasis,distant metastasis and vascular invasion of TNBC.CD47 can be used as a prognostic indicator and a potential target for immune therapy.
ABSTRACT
Adenoid cystic carcinoma (ACC) of the breast is a very rare and indolent tumor with a favorable prognosis, despite its triple-negative status. Due to its rarity, there has been no consensus regarding treatments, and treatment guidelines have not been established. Here, we report on six patients with ACC of the breast. All of the patients initially presented with localized disease and no axillary lymph node metastases. Although some of our patients developed local recurrence or distant metastases, all patients had a favorable clinical course, and to date, none of the patients has died from complications of her disease. Here, we described the clinicopathologic features of ACC of the breast and review the current literature.
Subject(s)
Humans , Adenoids , Breast Neoplasms , Breast , Carcinoma, Adenoid Cystic , Consensus , Glycogen Storage Disease Type VI , Lymph Nodes , Neoplasm Metastasis , Prognosis , RecurrenceABSTRACT
Adenoid cystic carcinoma (ACC) of the breast is a very rare and indolent tumor with a favorable prognosis, despite its triple-negative status. Due to its rarity, there has been no consensus regarding treatments, and treatment guidelines have not been established. Here, we report on six patients with ACC of the breast. All of the patients initially presented with localized disease and no axillary lymph node metastases. Although some of our patients developed local recurrence or distant metastases, all patients had a favorable clinical course, and to date, none of the patients has died from complications of her disease. Here, we described the clinicopathologic features of ACC of the breast and review the current literature.